Quick Answer
10x Genomics, Inc. reported Stockholders Equity of $796.33 million for fiscal year 2025.
10x Genomics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $796.33M | +12.1% |
| 2024 | $710.13M | -4.2% |
| 2023 | $741.04M | -8.0% |
| 2022 | $805.74M | -1.4% |
| 2021 | $817.57M | +10.6% |
| 2020 | $739.07M | +75.9% |
| 2019 | $420.08M | +291.0% |
| 2018 | -$219.99M | -95.5% |
| 2017 | -$112.51M | -16.7% |
| 2016 | -$96.43M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $785.12M | +8.6% | +1.5% |
| June 30, 2025 | $773.28M | +6.8% | +9.4% |
| March 31, 2025 | $706.89M | -1.7% | -0.5% |
| December 31, 2024 | $710.13M | -4.2% | -1.8% |
| September 30, 2024 | $722.80M | -3.0% | -0.2% |
| June 30, 2024 | $724.06M | -8.7% | +0.7% |
| March 31, 2024 | $718.83M | -10.4% | -3.0% |
| December 31, 2023 | $741.04M | -8.0% | -0.6% |
- 10x Genomics, Inc. showed an increase of +12.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2016–2025 period, 10x Genomics, Inc.’s stockholders equity has grown by 925.8% (from -$96.43 million to $796.33 million).
- The most recent figure is from 10x Genomics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: